Video Viewpoint (CE)

 

Release Date:    Friday, May 23, 2014
Expiration Date:    Friday, May 22, 2015
Estimated Time To Complete Activity:    1 hour, 15 minutes

 

AXIS Medical Education invites you to participate in this CME/CE-certified online activity entitled, ”Translating ASH Updates into Clinical Practice: A Video Viewpoint Discussion"Should you have any questions regarding educational credit for participating in this activity, please contact Postgraduate Institute for Medicine.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, hematologists, oncology nurses and other oncology healthcare professionals involved with the treatment of cancer.

Activity Overview

An overwhelming amount of new data is presented during the ASH Annual Meeting, highlighting the need to provide oncology and hematology healthcare professionals with access to the latest advances. It is imperative for these healthcare professionals to understand the wide range of therapeutic approaches and newer advances in the treatment of hematologic malignancies in order to optimize patient outcomes. The proposed Video Viewpoints (V2) activity seeks to meet these educational needs and bridge existing knowledge and performance gaps by addressing the most recent clinical advances in hematologic malignancies presented at the 2013 ASH Annual Meeting, and the relevance and integration of this new data to current practice to improve patient outcomes.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify emerging evidence reported at ASH 2013 with novel therapies on the horizon for the treatment of hematologic malignancies
  • Evaluate the safety, efficacy and tolerability data from recent and ongoing clinical trials reported at ASH 2013
  • Assess the implications of novel and emerging agents reported at ASH 2013 on clinical practice for the treatment of hematologic malignancies
  • Provide appropriate care and counsel for patients and their families
Chairperson and Moderator

Myron S. Czuczman, MD
Roswell Park Cancer Institute

Panel Members

Steven T. Rosen, MD, FACP
Feinberg School of Medicine at Northwestern University
Robert H. Lurie Comprehensive Cancer Center

Julie M. Vose, MD
University of Nebraska Medical Center

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.2 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. 

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Axel Grothey, MD - Mayo Clinic College of MedicineMyron S. Czuczman, MD
Roswell Park Cancer Institute

Advisory Board, Celgene Corporation, Mundipharma International Ltd., Onyx Pharmaceuticals, Inc., Teva Pharmaceuticals

Axel Grothey, MD - Mayo Clinic College of MedicineSteven T. Rosen, MD, FACP
Feinberg School of Medicine at Northwestern University
Robert H. Lurie Comprehensive Cancer Center

Advisory Board, Abbott Laboratories, Celgene Corporation, Chronic Lymphocytic Leukemia GRF, Genentech, Inc., MedNet Solutions, NanoSphere Inc.;Consultancies, Celgene Corporation, Cell Therapeutics, Inc., Genentech, Inc., Genzyme, Inc., Merck & Co., Inc., Seattle Genetics, Inc., Teva Pharmaceuticals, THERAKOS, Inc.; Contracted Research, Amgen, Inc., Avon Center for Excellence, Berlex Laboratories, Biogen IDEC Inc., CYTOGEN Corporation, Leukemia & Lymphoma Soc., Lynn Sage Cancer Res Found, Millennium & ILEX Partners, National Cancer Institute, Pharmacyclics, Inc., The Coleman Foundation, Wyeth-Amyerst Research;Honoraria, Hoag Hospital, International Lymphoma Symposium, Plexius Communications, The Medal Group; Speakers' Bureau, Celgene Corporation Speaker's Bureau, Cephalon Oncology Speaker's Bureau/Teva.

Axel Grothey, MD - Mayo Clinic College of MedicineJulie M. Vose, MD
University of Nebraska Medical Center
 

Advisory Board, KEW Group Inc.; Contracted Research, Allos Therapeutics/Spectrum, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., GlaxoSmithKline plc., Incyte Corporation, Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Pharmacyclics, Inc., sanofi US, US Biotest, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers, Linda King, MS, and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation

You will be required to login to the AXIS website to participate in this activity. Upon receiving a passing grade of 70% or better and completion of the evaluation form, you certificate will be available immediately.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

There is no fee for this educational activity.

Jointly sponsored/co-provided by


Postgraduate Institute for Medicine and AXIS Medical Education, Inc.

This activity is supported by an educational grant from Genentech.